

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims

Claims 1-68 (cancelled)

Claim 69 (previously presented): A pharmaceutical composition that induces tolerance to an antigen, said composition comprising a non-tumor lymphoid cell or non-tumor hematopoietic cell suitable for introduction into an individual and a pharmaceutically acceptable excipient, wherein said cell contains a nucleic acid sequence encoding a fusion protein operably linked to a promoter,

said fusion protein comprising (1) an immunoglobulin heavy chain or light chain; and (2) a polypeptide containing at least one epitope of the antigen;

wherein upon introduction to the individual said composition induces tolerance to the antigen in the individual.

Claim 70 (previously presented): The pharmaceutical composition of claim 69, wherein said nucleic acid sequence was introduced into the cell in a viral vector.

Claim 71 (previously presented): The pharmaceutical composition of claim 70, wherein said viral vector is selected from the group consisting of retroviral vector, and baculovirus vector.

Claim 72 (currently amended): The pharmaceutical composition of claim 70, wherein there are two or more copies of the nucleic acid sequence ~~encoding said fusion protein of claim 69 operatively linked to said promoter.~~

Claim 73 (previously presented): The pharmaceutical composition of claim 70, wherein the immunoglobulin is an IgG.

Claim 74 (currently amended): The pharmaceutical composition of claim 70, wherein said fusion protein comprises an N-terminal variable region of said heavy chain and has said polypeptide inserted adjacent to ~~the~~ first framework region of said N-terminal variable region.

Claim 75 (canceled)

Claim 76 (previously presented): The pharmaceutical composition of claim 70, wherein the cell is syngeneic with the individual.

Claim 77 (previously presented): The pharmaceutical composition of claim 70, wherein the cell is a bone marrow cell.

Claim 78 (previously presented): The pharmaceutical composition of claim 70, wherein the cell is a B-cell.

Claim 79 (previously presented): The composition of claim 69, wherein the cell is a hematopoietic cell.

Claim 80 (previously presented): The composition of claim 69 wherein the antigen is an autoimmune antigen.

Claim 81 (currently amended): The composition of claim 69 wherein the antigen is an allergen.